Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2005 February;53(1) > Minerva Cardioangiologica 2005 February;53(1):49-58

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Cardioangiologica 2005 February;53(1):49-58

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: English

New pharmacological protocols to prevent or reduce contrast media nephropathy

Briguori C., Airoldi F., Morici N., Colombo A.


PDF


Contrast media associated acute renal failure represents the third cause of in-hospital renal function deterioration after decreased renal perfusion and post-operative renal insufficiency. Although generally benign, this complication shows a mortality rate ranging from 3.8% to 64%, depending on the increase of creatinine concentration. The mechanism by which contrast-induced renal failure occurs is not well understood. Contrast agent-associated nephrotoxicity appears to be a result of direct contrast induced renal tubular epithelial cell toxicity and renal medullary ischemia. Furthermore, a key mechanism seems to be alteration in renal dynamics, probably caused by imbalances between vasodilator and vasocostrictor factors, including the activities of nitric oxide, prostaglandins, endothelin and reactive oxigen species. Recommendations to prevent contrast-associated nephrotoxicity are: 1) periprocedural hydration, 2) use of a low osmolality contrast, and 3) limiting the amount of contrast agent. Recently, considerable interest has resulted from the preliminary positive data on the effectiveness of prophylactic administration of antioxidant compounds (such as acetylcysteine and ascorbic acid) and fenoldopam.

top of page